Médica Sur, S.A. (MEDICAB) Fair Value & Analysis
Healthcare · MX · Market cap 5.4B MXN
Fair value as of: Jul 18, 2026
From 26 valuation models · updated 23 days ago
Share price −0.2% over the past month.
A strong business, screening 119% undervalued on our models.
What matters now
- The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (97.61 MXN). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range 13.20 MXN – 62.50 MXN · fair‑value band 97.61 MXN – 162.68 MXN · the 59.50 MXN price screens below the 130.14 MXN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Médica Sur, S.A. (MEDICAB) currently trades at 59.50 MXN, while our model-based Fair Value estimate is 130.14 MXN, implying the stock looks roughly 118.7% undervalued today. The Quality Score stands at 81/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Médica Sur, S.A. generated revenue of 4.8B MXN at a net margin of 11.1%. Revenue declined 0.9% year over year. It earns a return on equity of 20.7%. Net debt stands at 292M MXN. Fundamentals as of Jul 18, 2026
Our scenario range runs from 97.61 MXN (bear case) to 162.68 MXN (bull case); at 59.50 MXN, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 119%, MEDICAB screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (144.45 MXN) versus Asset-Based (18.50 MXN). Highest evidence: Growth DCF (80).
Notify me when MEDICAB reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 78 · Market factors (momentum, volatility) 72
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Médica Sur, S.A.B. de C.V. operates as a healthcare hospital in Mexico. The company offers angiology, vascular, and endovascular surgery; bariatric surgery; cancer; cardiology; checkup and preventive medicine; children; dental; emergency; endocrinology; gastroenterology, hepatology, and endoscopy; general surgery; geriatric; and gynecology and obstetrics …
Full company description
Médica Sur, S.A.B. de C.V. operates as a healthcare hospital in Mexico. The company offers angiology, vascular, and endovascular surgery; bariatric surgery; cancer; cardiology; checkup and preventive medicine; children; dental; emergency; endocrinology; gastroenterology, hepatology, and endoscopy; general surgery; geriatric; and gynecology and obstetrics services. It also provides specialized surgery; neonatology; neurology, neurosurgery, and gamma knife radiosurgery; neurophysiology; nuclear medicine; orthopedic and traumatology; outpatient surgery; plastic surgery; robotic surgery; spine microsurgery; transplant; urology; vascular disease; and imagine and MRI unit services. In addition, the company offers accommodation; concierge; digital hospital and telemedicine; gourmet; assistance in paperwork and filing procedures with insurer; and tour and transportation services. Further, it provides medical services and diagnosis. The company was incorporated in 1966 and is based in Mexico City, Mexico. Médica Sur, S.A.B. de C.V. operates as a subsidiary of Neuco, SA de CV.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Médica Sur, S.A. reported revenue of 4.8B MXN in FY2025 versus 3.9B MXN in FY2021, a compound +5.2%/yr. Reported net income was 540M MXN in FY2025, compounding −17.3%/yr from FY2021.
Watch MEDICAB: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Médica Sur, S.A. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Médica Sur, S.A. (MEDICAB) overvalued or undervalued?
What is the fair value of MEDICAB?
What is the quality score of MEDICAB?
What is the revenue of Médica Sur, S.A. (MEDICAB)?
What is the net profit margin of MEDICAB?
Does Médica Sur, S.A. pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Médica Sur, S.A. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.